Overlooked Stocks: ADGI, NRXP, SGRY

<p>Adagio Therapeutics (ADGI) stock price was up around 86% today. The clinical-stage biopharmaceutical company focuses on antibody-based solutions for infectious diseases. Currently, it is developing "ADG20" for the treatment and prevention of Covid-19. NRX Pharmaceuticals (NRXP) stock price was up 20% today. The clinical-stage small molecule pharmaceutical company stock spiked today following news of its ZYESAMI Covid-19 treatment. Finally, George Tsilis discusses Surgery Partners (SGRY) as the stock was upgraded to buy from hold at Stifel with a $51 price target.</p><p><br></p>